Literature DB >> 1318998

Analysis of an immunodominant epitope of topoisomerase I in patients with systemic sclerosis.

T M Meesters1, M Hoet, F H van den Hoogen, R Verheijen, W J Habets, W J van Venrooij.   

Abstract

In this paper an immunodominant epitope of Topoisomerase I is described. An epitope expression sublibrary was constructed from Topoisomerase I cDNA. The subclones were screened with an antiserum from a patient with systemic sclerosis (SSc). The positive clones defined one immunodominant B cell epitope (epitope III), which was located at the carboxyterminal part of the protein. The epitope, 52 amino acids in length, neither contains the p30gag sequence nor the suggested active site Tyr-723, both presumed antibody recognition sites. More than 70% of our anti-TopoI sera recognize this epitope III, indicating that it is a major recognition site of the anti-TopoI autoantibodies in SSc sera. DNA relaxation experiments show that all sera that recognize epitope III and most sera with antibodies to other epitopes inhibit Topoisomerase I activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318998     DOI: 10.1007/bf00419757

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  26 in total

Review 1.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Epitope patterns of anti-RNP antibodies in rheumatic diseases. Evidence for an antigen-driven autoimmune response.

Authors:  W J Habets; M H Hoet; W J van Venrooij
Journal:  Arthritis Rheum       Date:  1990-06

3.  Scl-86, a marker antigen for diffuse scleroderma.

Authors:  W J van Venrooij; S O Stapel; H Houben; W J Habets; C G Kallenberg; E Penner; L B van de Putte
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

4.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Small nuclear RNA-associated proteins are immunologically related as revealed by mapping of autoimmune reactive B-cell epitopes.

Authors:  W J Habets; P T Sillekens; M H Hoet; G McAllister; M R Lerner; W J van Venrooij
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase.

Authors:  G G Maul; B T French; W J van Venrooij; S A Jimenez
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I.

Authors:  W K Eng; S D Pandit; R Sternglanz
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

8.  A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30gag antigen.

Authors:  C C Query; J D Keene
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

9.  Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease.

Authors:  W J Habets; D J de Rooij; M H Salden; A P Verhagen; C A van Eekelen; L B van de Putte; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

10.  cDNA cloning of the human U1 snRNA-associated A protein: extensive homology between U1 and U2 snRNP-specific proteins.

Authors:  P T Sillekens; W J Habets; R P Beijer; W J van Venrooij
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  2 in total

Review 1.  B-cell epitopes of scleroderma-specific autoantigens.

Authors:  R Verheijen
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  Detection of anti-topoisomerase I antibodies using a full length human topoisomerase I recombinant protein purified from a baculovirus expression system.

Authors:  J Whyte; W C Earnshaw; J J Champoux; L H Parker; L Stewart; N D Hall; N J McHugh
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.